Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Background: Nonalcoholic steatohepatitis (NASH) is an active form of nonalcoholic fatty liver disease. Risk factors for NASH include type 2 diabetes mellitus (T2DM) and obesity. Sodium–glucose cotransporter 2 (SGLT2) inhibitors used to treat T2DM prevent glucose reabsorption in the kidney and increa...

Full description

Bibliographic Details
Main Authors: Hiroshi Tobita, MD, PhD, Shuichi Sato, MD, PhD, Tatsuya Miyake, MD, PhD, Shunji Ishihara, MD, PhD, Yoshikazu Kinoshita, MD, PhD
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Current Therapeutic Research
Subjects:
nonalcoholic
steatohepatitis
type 2 diabetes mellitus
sodium–glucose
cotransporter 2-inhibitor
dapagliflozin
open-label
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X17300061

Internet

http://www.sciencedirect.com/science/article/pii/S0011393X17300061

Similar Items